EAM
AKBA icon

Empirical Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Empirical Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.9K Hold
35,000
– – 0.01% 448
2026
Q1 		$48.6K Hold
35,000
– – 0.01% 396
2025
Q4 		$56.4K Buy
35,000
+15,000
+75% +$31.4K 0.02% 345
2025
Q3 		$54.6K Buy
+20,000
New +$66.5K 0.02% 358
2025
Q2 		– Sell
-10,000
Closed -$19.2K – 315
2025
Q1 		$19.2K Sell
10,000
-3,300
-25% -$6.74K 0.01% 300
2024
Q4 		$25.3K Sell
13,300
-20,400
-61% -$35.4K 0.01% 414
2024
Q3 		$44.5K Buy
+33,700
New +$45K 0.02% 292

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Empirical Asset Management's AKBA Position: Q2 2026 in Review

Empirical Asset Management held its Akebia Therapeutics (AKBA) position steady in Q2 2026 at 35,000 shares worth $39.9K. The position accounts for 0.01% of the portfolio, ranked #448.

Empirical Asset Management first reported a position in AKBA in Q3 2024 and has held it in 7 quarters since. The position peaked at $56.4K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Empirical Asset Management held 35,000 shares of Akebia Therapeutics worth $39.9K as of Q2 2026.
  • Empirical Asset Management left its Akebia Therapeutics share count unchanged in Q2 2026.
  • Akebia Therapeutics made up 0.01% of Empirical Asset Management's portfolio in Q2 2026, its #448 holding.
  • Empirical Asset Management first reported a position in Akebia Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Empirical Asset Management's Akebia Therapeutics position peaked at $56.4K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Empirical Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.